A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Relapsed/refractory Mantle Cell Lymphoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients must have been refractory to and/or relapsed/progressed after at least 1 prior therapy. 2. Patients must have a current or prior tissue sample that is IHC positive for cyclin D1 or that is positive by FISH or cytogenetics

You may not be eligible for this study if the following are true:

  • 1. Patients must not have received systemic treatment for Mantle Cell Lymphoma (MCL) for at least 14 days prior to enrollment. 2. Patients may not have current/active Central Nervous System (CNS) involvement with mantle cell lymphoma 3. Patients may not have another malignancy that could interfere with the evaluation of safety or efficacy of this combination


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.